Grazoprevir

CAT#: H326651

CAS#: 1350514-68-9

Description: Grazoprevir, also known as MK5172, is a drug approved for the treatment of hepatitis C. Grazoprevir is a second generation hepatitis C virus protease inhibitor acting at the NS3/4a protease targets. It has good activity against a range of HCV genotype variants, including some that are resistant to most currently used antiviral medications.

img

Synthetic Routes

Grazoprevir - Synthetic Route 1

Grazoprevir route01

Synthetic reference

Grazoprevir - Synthetic Route 2

Grazoprevir route02

Synthetic reference

Grazoprevir - Synthetic Route 3

Grazoprevir route03

Synthetic reference

Grazoprevir - Synthetic Route 4

Grazoprevir route04

Synthetic reference

Yasuda, Nobuyoshi; Kuethe, Jeffrey T.; Humphrey, Guy; Beutner, Gregory L.; Zhong, Yong-Li; Cleator, Edward; Baxter, Carl. Methods and intermediates for preparing macrolactam peptidomimetic HCV protease inhibitors. Assignee Merck Sharp & Dohme Corp., USA; Merck Sharp & Dohme Limited. WO 2013028471. 2013.

Grazoprevir - Synthetic Route 5

Grazoprevir route05

Synthetic reference

Xu, Feng; Humphrey, Guy; Pei, Tao; Song, Zhiguo Jake; Wang, Tao; Artino, Laura. Methods and intermediates for preparing macrolactam peptidomimetic HCV protease inhibitors. Assignee Merck Sharp & Dohme Corp., USA. WO 2013028470. 2013.

Grazoprevir - Synthetic Route 6

Grazoprevir route06

Synthetic reference

Trinius, Frank. Packaging comprising administration units of a crystalline form of the Nedd8-activating enzyme inhibitor [(1S,2S,4R)-4-[[6-[((1R,2S)-5-chloro-2-methoxy-2,3-dihydro-1H-inden-1-yl)amino]pyrimidin-4-yl]oxy]-2-hydroxycyclopentyl]methyl sulfamate hydrochloride. Assignee IP Gesellschaft Fuer Management mbH, Germany. EP 2764866. 2014.